TABLE 1.
Summary of existing literature on solid organ transplantation from COVID‐19 positive organ donors
| Reference | Donor information | Organ transplanted | Recipient fully vaccinated | Recipient with prior COVID‐19 infection | Recipient serostatus at the time of transplant | Recipient develop COVID‐19? | Recipient receive COVID‐19 therapy? | Graft outcome |
|---|---|---|---|---|---|---|---|---|
| Puodziukaite 1 |
Mild symptoms, NPS+ CT values* = 32.0; 33.8 |
Kidney | No | Yes | IgG + | No | No | Good |
| Kidney | No | Yes | IgG+ | No | No | Good | ||
| Meshram 2 |
Donor with critical COVID‐19 infection: NPS – at the time of organ procurement |
Kidney | No | No | NR | No | No | Good |
| Kidney | No | Yes | NR | No | No | Good | ||
| de la Villa 3 |
Mild COVID infection 2 months prior NPS+ CT value † = 30, Plasma PCR – |
Heart | NR | No | IgG– | No | No | NR |
| Liver | NR | Yes | IgG+ | No | No | NR | ||
| Frattaroli 4 |
No history of COVID‐19 symptoms NPS+ CT value ‡ = 40.2 |
Kidney | No | NR | NR | No | No | Good |
| Kidney | No | NR | NR | No | No | Good | ||
|
COVID‐19 infection during terminal hospitalization; NPS – at the time of organ procurement |
Kidney | No | NR | NR | No | No | Good | |
| Liver | Yes | NR | NR | No | No | Good | ||
| Sigler 5 |
NPS+ CT values † = 29.45, 31 |
Heart | No | No | IgG– | No | Remdesivir + casirivimab/imdevimab | Good |
| Kidney | No | NR | IgG– | No | Remdesivir | Good | ||
| Kidney | Yes | NR | IgG– | No | Remdesivir | Good | ||
| Koval 11 |
NPS+ IgG+ |
Kidney | No | No | NR | No | No | Good |
| Kidney | No | No | NR | No | No | Good | ||
|
NPS+ CT values † = 40; 38 |
Kidney | No | Yes | NR | No | No | Good | |
| Kidney | No | No | NR | No | No | Good | ||
| NPS+ | Kidney | No | No | NR | No | No | Good | |
| Kidney | No | Yes | NR | No | No | Good | ||
| NPS+ | Kidney | No | Yes | NR | No | No | Good | |
| Kidney | No | No | NR | No | No | Good | ||
|
NPS+, CT values † = 31, 41 |
Kidney | No | No | NR | No | No | Good | |
| Kidney | No | No | NR | No | No | Good | ||
| Hong 12 |
Mild symptoms NPS+, 4.2 log copies/ml |
Partial Liver | No | No | NR | No | Lopinavir + ritonavir followed by hydroxychloroquine | Not reported |
| Manzia 13 |
No known symptoms BAL+, CT values § = 24; 27; 24 |
Liver | No | Yes: Recipient+ on BAL and NP swab | IgG+ | Recipient already NPS+ at the time of transplant | No | Good |
| Dhand 14 |
Early mild‐moderate COVID‐19, NPS+ CT value*: 38.5; 40.5 |
Heart | NR | NR | NR | No | casirivimab/imdevimab | Good |
| Liver | Yes | NR | NR | No | casirivimab/imdevimab | Good | ||
| Kaul 6 |
NPS– BAL+ CT values ¶ = 8.5; 9.5 |
Lung | NR | NR | NR | Yes | Remdesivir and convalescent plasma | Attributable death |
| Perlin 15 | NPS+ | Kidney | NR | NR | IgG– | No | No | Delayed graft function |
| Kidney | NR | NR | IgG– | No | No | Good | ||
| Ngueyn 16 | NPS+ | Partial Liver | NR | NR | IgG– | No | Convalescent plasma | Good |
| Kumar 7 |
NPS– BAL+ |
Lung | NR | NR | NR | Yes | Two courses Remdesivir + methylprednisolone | Prolonged stay in intensive care unit with new oxygen requirement |
| Liver | NR | NR | NR | No | No | Good | ||
| Kidney | NR | NR | NR | No | No | Non‐attributable mortality | ||
| Kidney | NR | NR | NR | No | No | Good | ||
|
NPS– BAL+ |
Kidney | NR | NR | NR | No | No | Good |
Abbreviations: BAL, bronchoalveolar lavage; CT, cycle threshold; IgG, SARS‐CoV‐2 immunoglobulin G; NPS, nasopharyngeal swab; NR, not reported.
GeneXpert SARS‐COV‐2 Cepheid platform.
Platform not specified.
Labcorp.
Allplex SARS‐CoV‐2 assay Seegene.
DiaSorin molecular.